Insilico Medicine Doses First Patient in Phase III Trial of AI-Developed IPF Drug
Insilico Medicine has dosed the first patient in GENESIS-IPF-3, a Phase III trial for its generative AI-developed drug, Rentosertib, for idiopathic pulmonary fibrosis (IPF).
Insilico Medicine, a clinical-stage biotechnology company utilizing generative artificial intelligence, has administered the first dose in its GENESIS-IPF-3 study. This marks the initiation of a Phase III clinical trial for Rentosertib, the company's internally developed drug candidate for idiopathic pulmonary fibrosis (IPF).
The trial is investigating Rentosertib's efficacy and safety in patients suffering from IPF, a progressive and irreversible lung disease with limited treatment options and poor prognosis. The move to Phase III follows earlier studies that have provided data supporting further development.
GENESIS-IPF-3 is designed as a randomized, double-blind, placebo-controlled study conducted across multiple sites. The primary goal is to assess the impact of Rentosertib on lung function decline and disease progression in IPF patients. The outcomes will be critical for the company's strategic future in IPF treatment.
Insilico Medicine employs generative AI across its drug discovery and development pipeline, aiming to accelerate the identification and advancement of novel therapeutics. The progression of Rentosertib into a large-scale Phase III trial signifies a key milestone in the company's strategy to leverage AI in addressing significant unmet medical needs.